Lọc tín hiệu

IMP

Imexpharm Corporation
PharmaceuticalsHOSE
Same sector:AGPAMPBCHBCPBIOCDPCNCDANDBDDBM
35.550
−2,87%
2026-10-19

Fundamental Analysis

52 / 100BRubric: Manufacturing
Quarterly resultsRelative Valuation
CriterionLatest Q EPS growth (YoY)Avg EPS growth, last 3 (YoY)Quarters with EPS growthRevenue growth (YoY)Gross margin change (pp, YoY)Net margin change (pp, YoY)Return on Equity (TTM)Financial health (Debt/Equity)Valuation (P/E vs 5-yr median)Revenue (bn)Rev YoYNPAT (bn)NPAT YoYP/E5-Year Median P/EP/E vs. 5-Year Median
Value+4.0%+1.1%2 / 3-11.1%+1.81 pp+2.43 pp+15.6%0.0815.19562−11,1%93,9+4,0%15.1923.16−34,4%
Pts008081241212
Valuation annotation:Price: 35.550 (close price on 2026-10-19)EPS (TTM): 2.340

Financial charts

1.Revenue & growth

VND bn562Q2/26

1.Revenue & growth

VND bn562Q2/26

2.Profit & growth

VND bn93,9Q2/26

3.Profit mix (Penman)

VND bn457Q2/26

4.Margins & cost structure

%42.0%Q2/26

5.Returns & cash cycle

% · days17.7%Q2/26

6.Earnings quality & cash

VND bn258Q2/26

7.Asset structure

VND bn2.947Q2/26

8.Funding & debt health

VND bn · times2.947Q2/26

9.Revenue backlog

VND bn49,5Q2/26

10.Valuation

times · %15,2×Q2/26

11.EPS growth & dilution warning (CANSLIM)

VND per share; growth in %610Q2/26
Adjusted EPS growth, latest quarter
4.0%
Average adjusted EPS growth, 3 quarters
1.1%
Quarters at 25%+ growth
0/3
Share dilution rate, 1 year
0.0%

Source: vnstockData through Q2/26